Article Versions Notes

Christopoulos P, Girard N, Proto C, Soares M, Lopez PG, van der Wekken AJ, Popat S, Diels J, Schioppa CA, Sermon J, et al. Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations. Cancers. 2023; 15(22):5326. https://doi.org/10.3390/cancers15225326

Christopoulos, Petros, Nicolas Girard, Claudia Proto, Marta Soares, Pilar Garrido Lopez, Anthonie J. van der Wekken, Sanjay Popat, Joris Diels, Claudio A. Schioppa, Jan Sermon, and et al. 2023. "Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations" Cancers 15, no. 22: 5326. https://doi.org/10.3390/cancers15225326

Christopoulos, P., Girard, N., Proto, C., Soares, M., Lopez, P. G., van der Wekken, A. J., Popat, S., Diels, J., Schioppa, C. A., Sermon, J., Rahhali, N., Pick-Lauer, C., Adamczyk, A., Penton, J., & Wislez, M. (2023). Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations. Cancers, 15(22), 5326. https://doi.org/10.3390/cancers15225326